H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) today. The company's shares closed last Monday at $0.38, close to its 52-week low of $0.28. According to TipRanks.com, Arce is a 4-star analyst with an average return of 12.8% and a 39.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals. Iterum Therapeutics has an analyst consensus of Hold. See Insiders’ Hot Stocks on TipRanks >> Based on Iterum Therapeutics' latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $3.74 million.
https://www.tipranks.com/news/blurbs/iterum-therapeutics-itrm-gets-a-hold-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Iterum Therapeutics Charts.
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Iterum Therapeutics Charts.